Case Reports

In Rematec v Europe Forestry, the UPC Court of Appeal overturned the Mannheim Local Division’s revocation of the patent and, applying Article 75(1) UPCA, issued a final decision on both validity and infringement despite no infringement finding at first instance. The Court adopted a narrower, description‑led approach to claim interpretation, confirmed the patent’s validity, found infringement, and granted final remedies without referring the case back to the Court of First Instance.

In Syntorr v Arthrex, the UPC Court of Appeal clarified that while litigation insurance is not itself a form of security under Rule 158 RoP, it is a relevant factor when deciding whether security for costs should be ordered at all. By failing to consider the claimant’s insurance policy, the Munich Local Division wrongly exercised its discretion. The Court set aside the €2 million security order and confirmed that insurance can mitigate concerns about cost recoverability.

In Fives v REEL, the Hamburg Local Division of the UPC dismissed a standalone damages action despite prior findings of infringement. Although the UPC was competent to assess damages, the court held that national law applied because the relevant events pre‑dated the UPC’s entry into force. Applying German law, the court found that the claimant had not proven causation or lost profit, highlighting the demanding evidentiary burden for price‑reduction damages claims and the importance of substantiating counterfactual tender outcomes.

In Dyson v Dreame, the UPC Court of Appeal issued its first preliminary reference to the Court of Justice of the European Union. The referral concerns the scope of UPC jurisdiction where a non‑EU manufacturer is sued alongside an EU‑based intermediary acting as an authorised representative, and whether provisional measures may extend to non‑UPC states such as Spain. The decision places important questions about anchor defendants, intermediaries and the UPC’s long‑arm jurisdiction before the CJEU.

The UPC Court of Appeal has clarified that where jurisdiction is based on Article 7(2) of the Brussels Regulation (place of harm), it is limited to damage occurring within UPC territory. In Keeex v Adobe, the Court set aside the Paris Local Division’s decision to hear infringement claims relating to non‑UPCA states, confirming that broader territorial reach requires satisfaction of the strict conditions under Article 71b(3).

In KeyMed v PR Medical, the Milan Local Division of the Unified Patent Court rejected a preliminary objection seeking to change the language of proceedings from English to Italian under Rule 14.2(b) RoP. Although the defendant was an Italian company and the action was brought before the Italian local division, the court held that the language protection did not apply because the alleged infringement was not confined to Italy.

IMC Créations is a French company specialising in anti-theft systems for vehicles, particularly commercial vehicles. Among other things, it sells locks for the side and rear doors of commercial vehicles. Mul-T-Lock belongs to the Assa Abloy group and specialises in high security locking and access control systems, in particular pick-resistant keys and locks. IMC alleged that Mul-T-Lock’s MPV 1000 padlock infringes its unitary patent EP4153830 and the corresponding Swiss national validation.

The dispute arises out of earlier proceedings between Heraeus Electronics GmbH & Co. KG (claimant) and Vibrantz GmbH (defendant), relating to European Patent No. 3215288. The Munich Local Division issued a substantive decision on 10 October 2025 addressing infringement and a counterclaim for revocation. Among other findings, the court partially revoked the patent in three Contracting Member States and dismissed the infringement action. In its cost decision, the court apportioned 40% of the costs to the defendant and 60% to the claimant.

It was foreseen that the requirements of the Unitary Patent Regulation (1257/2012) might result that old European patent applications (effective filing date before 1 March 2007) could be ineligible for unitary patent protection. The UPC has now confirmed the view of the EPO that this is indeed the case.

The UPC Mannheim Local Division revoked Centripetal’s patent relating to automated cyber‑event analysis, finding the claimed combination of static and machine‑learned algorithms anticipated by prior art (HAWK) and additional amendments lacking inventive step. With the patent invalidated in Germany and France, the infringement claim against Palo Alto Networks was dismissed. An appeal to the UPC Court of Appeal remains possible.

The UPC Munich Local Division invalidated Sanofi’s cabazitaxel patent, finding that Phase III clinical trial disclosures created a reasonable expectation of success—departing from the EPO’s earlier conclusion.

The UPC Court of Appeal’s November 2025 decisions in Amgen v. Sanofi and Meril v. Edwards provide the most comprehensive guidance to date on inventive step, claim construction, sufficiency, added matter, and procedural rules. The Court clarified how the “objective problem” should be formulated, reinforced the need for a clear pointer or motivation for obviousness, and aligned many principles with established EPO and national case law. The judgments also address injunctions, proportionality, costs, competence, and amendment admissibility—making them essential reading for anyone navigating UPC litigation.

Hurom v. NUC UPC-CFI_162/2024 LD Mannheim Decision of 2 October 2025

In the latest Eli Lilly v HGS ruling, the Court of Appeal has found HGS antibody claims to be sufficient, given the Supreme Court has already held the claims to be capable of industrial applicability.

The Patents Court has issued another judgment expressing dissatisfaction with the CJEU’s ruling in Medeva (C-322/10). In particular, the Court has held that in order to determine if a particular...

A High Court decision last month has provided guidance on how Article 110(1) of the Community Designs Regulation 6/2002/EC, which relates to the protection of designs for component parts of complex...

Woolley v Ultimate Products Ltd[2012] EWCA Civ 1038 (26 July 2012)Upholding a decision of the High Court, the Court of Appeal considered the effect of a licence, consumer confusion “the wrong way”...

In the UK, applications to declare a UK registered design invalid can be filed at the UK Intellectual Property Office (UKIPO), whereupon the case is decided by a Hearing Officer of the UKIPO acting...

The UK Intellectual Property Office (UK IPO) has recently published a consultation document on the proposed reform of the UK Designs Legal Framework.

A Patents County Court judgment by HHJ Birss QC in Gimex v Chill Bag provides guidance on whether the indication of the product in a registered design has any bearing when assessing validity and...

Interflora Inc & Anor v Marks and Spencer Plc & Anor [2012] EWHC 1722 (Ch)In a wider action concerning the alleged infringement of two of Interflora’s trademarks through Marks & Spencer’s use of...

On 4 July in Phillips v Mulcaire [2012] UKSC 28 the Supreme Court of the United Kingdom gave judgment on two key issues regarding the privilege against self-incrimination.

The Court of Appeal recently allowed an appeal by Budejovicky Budvar Narodni Podnik (BB), against a decision that found its “Budweiser” mark invalid following an attack by Anheuser-Busch (AB) which...

(HTC Europe Co Ltd v Apple Inc [2012] EWHC 1789).A further decision in the so-called “smartphone wars” was issued by the High Court recently in relation to a patent dispute between HTC Europe Co Ltd...

In addition to an earlier summary by Darren Smyth of the ruling in Generics (t/a Mylan) v Yeda and Teva, Darren has provided further analysis for the IPKat.

Today’s ruling by Mr Justice Arnold (Patents Court, England and Wales) in Generics (t/a Mylan) v Yeda and Teva has been summarised by Darren Smyth for the IPKat.

Samsung has won a longstanding battle with Apple concerning one of Apple's Registered Community Designs for its tablet computers.The decision is significant because it represents the first...

Generics (UK) Ltd v Yeda Research & Development Co Ltd & Teva Pharmaceutical Industries[2012] EWCA Civ 726The Court of Appeal has overturned an injunction that prevented an in-house patent attorney...